Anusha Abdullah

Dr. Anusha Abdullah


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KOKatharina Theresa Obermeier
Katharina Theresa Obermeier
JHJens Tobias Hartung
Jens Tobias Hartung
THTim Hildebrandt
Tim Hildebrandt
IDIna Dewenter
Ina Dewenter
WSWenko Smolka
Wenko Smolka
AAAnusha Abdullah
Anusha Abdullah
A total of 7% of all benign bone lesions are diagnosed as fibrous dysplasia (FD). The symptoms of FD of the jaw range from asymptomatic to dental anomalies, pain and facial asymmetry. Due to its resemblance to other fibro-osseous bone lesions, misdiagnosis often occurs and can lead to inadequate treatment. Particularly in the jaw, this lesion does not become quiescent during puberty, making fundamental knowledge about the diagnosis and treatment of FD crucial. Mutational analysis and nonsurgical approaches offer new diagnostic and therapeutic options. In this review, we examine the advances and the difficulties of the diagnosis and the various treatment modalities of FD of the jaw in order to capture the current scientific knowledge on this bone disease.

7 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AAAnusha Abdullah
Anusha Abdullah
SWSabina Noreen Wuersching
Sabina Noreen Wuersching
MKMaximilian Kollmuss
Maximilian Kollmuss
PPPhilipp Poxleitner
Philipp Poxleitner
IDIna Dewenter
Ina Dewenter
KOKatharina Theresa Obermeier
Katharina Theresa Obermeier
X-linked hypophosphatemia is a rare, hereditary disorder that significant influences teeth and alveolar bone. The first clinical sign leading to the diagnosis of X-linked hypophosphatemia is often dental impairment with dental abscesses and dentin mineralization defects. Genetic analysis helped find the responsible gene and therefore opened up new ways of therapeutically managing X-linked hypophosphatemia. The human monoclonal antibody Burosumab represents a milestone in the targeted therapy of this hereditary disease by directly addressing its pathophysiology. Targeted therapy has been shown to improve skeletal impairment, pain, and phosphate metabolism. However, the influence of this new therapy on dental impairment has only been addressed in a few recent studies with varying results. Therefore, in this review, we aim to summarize the dental phenotype and analyze the different treatment modalities with a focus on dental impairment.